
@article{ray-coquardOlaparibBevacizumabFirstLine2019,
  title = {Olaparib plus {{Bevacizumab}} as {{First}}-{{Line Maintenance}} in {{Ovarian Cancer}}},
  author = {Ray-Coquard, Isabelle and Pautier, Patricia and Pignata, Sandro and Pérol, David and González-Martín, Antonio and Berger, Regina and Fujiwara, Keiichi and Vergote, Ignace and Colombo, Nicoletta and Mäenpää, Johanna and Selle, Frédéric and Sehouli, Jalid and Lorusso, Domenica and Guerra Alía, Eva M. and Reinthaller, Alexander and Nagao, Shoji and Lefeuvre-Plesse, Claudia and Canzler, Ulrich and Scambia, Giovanni and Lortholary, Alain and Marmé, Frederik and Combe, Pierre and de Gregorio, Nikolaus and Rodrigues, Manuel and Buderath, Paul and Dubot, Coraline and Burges, Alexander and You, Benoît and Pujade-Lauraine, Eric and Harter, Philipp},
  options = {useprefix=true},
  date = {2019-12-19},
  journaltitle = {New England Journal of Medicine},
  volume = {381},
  number = {25},
  eprint = {31851799},
  eprinttype = {pmid},
  pages = {2416--2428},
  publisher = {{Massachusetts Medical Society}},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa1911361},
  url = {https://doi.org/10.1056/NEJMoa1911361},
  urldate = {2020-11-20},
  annotation = {\_eprint: https://doi.org/10.1056/NEJMoa1911361},
  file = {C\:\\Users\\cmc\\Zotero\\storage\\N9LVX8ZS\\Ray-Coquard et al. - 2019 - Olaparib plus Bevacizumab as First-Line Maintenanc.pdf;C\:\\Users\\cmc\\Zotero\\storage\\P6ET2QIK\\nejmoa1911361.html}
}


